All awarded grants

Novo Nordisk Foundation has awarded a grant of USD 2,200,000 to support the development of a novel class of pan-coronavirus antivirals

Open Philanthropy has awarded a grant of USD 3,550,000 to support development of Influenza A polymerase inhibitors

The Novo Nordisk Foundation has awarded a grant of GBP 1,933,861 to support pandemic influenza antiviral discovery.

The Novo Nordisk Foundation has awarded a grant of EUR 1,860,959 to support development of precision glycol-oligomers as hetero-multivalent pandemic influenza virus blockers.

The Novo Nordisk Foundation has awarded a grant of DKK 13,834,409 to Melbourne researchers to support the late pre-clinical development of a novel long-acting pan-influenza antiviral drug that will be accessible for people in low- and middle-income countries.

The Novo Nordisk Foundation has awarded a grant of CHF 1,250,024 to promote Henipavirus antiviral development.

Bill & Melinda Gates Foundation has awarded a grant of USD 2,178,521 to support identification of conformational modulators of influenza virus M1 protein as antivirals with a high barrier to resistance for pandemic preparedness.

The Novo Nordisk Foundation has awarded a grant of EUR 1,760,761 to support influenza antiviral development.

Open Philanthropy has awarded a grant of USD 2,200,000 to support optimization of a host-directed Influenza A antiviral

Open Philanthropy made an investment of $1,000,000 to support development of drugs that inactivate influenza virus.